X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Merck Ltd with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

MERCK LTD vs AUROBINDO PHARMA - Comparison Results

MERCK LTD    Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    MERCK LTD AUROBINDO PHARMA MERCK LTD/
AUROBINDO PHARMA
 
P/E (TTM) x 44.1 19.4 227.3% View Chart
P/BV x 6.4 3.6 176.7% View Chart
Dividend Yield % 0.5 0.3 153.4%  

Financials

 MERCK LTD   AUROBINDO PHARMA
EQUITY SHARE DATA
    MERCK LTD
Dec-17
AUROBINDO PHARMA
Mar-18
MERCK LTD/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,358809 167.8%   
Low Rs933504 185.1%   
Sales per share (Unadj.) Rs665.0281.1 236.6%  
Earnings per share (Unadj.) Rs56.641.4 136.8%  
Cash flow per share (Unadj.) Rs72.550.9 142.4%  
Dividends per share (Unadj.) Rs15.002.50 600.0%  
Dividend yield (eoy) %1.30.4 343.9%  
Book value per share (Unadj.) Rs441.7199.4 221.6%  
Shares outstanding (eoy) m16.60585.88 2.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.72.3 73.7%   
Avg P/E ratio x20.215.9 127.5%  
P/CF ratio (eoy) x15.812.9 122.5%  
Price / Book Value ratio x2.63.3 78.7%  
Dividend payout %26.56.0 438.6%   
Avg Mkt Cap Rs m19,011384,630 4.9%   
No. of employees `0001.517.3 8.9%   
Total wages/salary Rs m1,69621,308 8.0%   
Avg. sales/employee Rs Th7,150.09,500.7 75.3%   
Avg. wages/employee Rs Th1,098.71,229.4 89.4%   
Avg. net profit/employee Rs Th608.21,397.9 43.5%   
INCOME DATA
Net Sales Rs m11,040164,666 6.7%  
Other income Rs m2401,020 23.5%   
Total revenues Rs m11,279165,686 6.8%   
Gross profit Rs m1,37637,718 3.6%  
Depreciation Rs m2645,580 4.7%   
Interest Rs m0777 0.0%   
Profit before tax Rs m1,35232,380 4.2%   
Minority Interest Rs m031 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1700-   
Tax Rs m5838,183 7.1%   
Profit after tax Rs m93924,229 3.9%  
Gross profit margin %12.522.9 54.4%  
Effective tax rate %43.125.3 170.6%   
Net profit margin %8.514.7 57.8%  
BALANCE SHEET DATA
Current assets Rs m7,523121,878 6.2%   
Current liabilities Rs m2,25386,806 2.6%   
Net working cap to sales %47.721.3 224.2%  
Current ratio x3.31.4 237.9%  
Inventory Days Days52130 40.2%  
Debtors Days Days4168 59.3%  
Net fixed assets Rs m1,24081,037 1.5%   
Share capital Rs m166586 28.3%   
"Free" reserves Rs m7,167116,218 6.2%   
Net worth Rs m7,333116,804 6.3%   
Long term debt Rs m04,512 0.0%   
Total assets Rs m9,912211,052 4.7%  
Interest coverage xNM42.7-  
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.10.8 142.7%   
Return on assets %9.511.8 80.0%  
Return on equity %12.820.7 61.7%  
Return on capital %20.827.4 75.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m1,01580,727 1.3%   
Fx outflow Rs m3,04334,700 8.8%   
Net fx Rs m-2,02846,027 -4.4%   
CASH FLOW
From Operations Rs m53719,548 2.7%  
From Investments Rs m-476-19,570 2.4%  
From Financial Activity Rs m-2208,642 -2.5%  
Net Cashflow Rs m-1608,922 -1.8%  

Share Holding

Indian Promoters % 0.0 54.1 -  
Foreign collaborators % 51.8 0.0 -  
Indian inst/Mut Fund % 18.2 8.0 228.9%  
FIIs % 1.0 27.7 3.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.1 10.2 285.3%  
Shareholders   28,591 69,601 41.1%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare MERCK LTD With:   DR. DATSONS LABS  STRIDES PHARMA SCIENCE  TTK HEALTHCARE  JUBILANT LIFE SCIENCES  BIOCON LTD  

Compare MERCK LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

From Urjit Patel to Shaktikanta Das; What Lies Ahead?(Podcast)

The week gone by saw Sensex plunge from 700 points to rise by over 600 points. With a volatile and eventful week, it was a challenge keeping up with the news every day.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 21.6% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (down 21.6% YoY). Sales on the other hand came in at Rs 48 bn (up 7.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

MERCK LTD Announces Quarterly Results (2QFY19); Net Profit Up 29.8% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, MERCK LTD has posted a net profit of Rs 411 m (up 29.8% YoY). Sales on the other hand came in at Rs 2 bn (down 27.7% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)

Dec 6, 2018

My latest StockSelect recommendation ticks all the boxes of a great safe stock.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

Are Foreign Investors Heading Back to the Indian Stock Markets?(Chart Of The Day)

Dec 3, 2018

After months of heavy FII selling, November witnessed a return on foreign money into Indian equities...

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

MERCK LTD SHARE PRICE


Dec 14, 2018 (Close)

TRACK MERCK LTD

  • Track your investment in MERCK LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MERCK LTD - CADILA HEALTHCARE COMPARISON

COMPARE MERCK LTD WITH

MARKET STATS